28 citations
,
June 2003 in “Applied immunohistochemistry & molecular morphology” Combining cell conditioning with mild protease digestion effectively shows versican mRNA in mouse skin sections.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
More research is needed to understand chemotherapy-induced hair loss and its phases.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
9 citations
,
September 2024 in “Frontiers in Endocrinology” Platelet-rich plasma infusion improved pregnancy outcomes for women with thin endometrium.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
January 2024 in “Wiadomości Lekarskie” CAR-T therapy offers hope for children with hard-to-treat blood cancers.
26 citations
,
December 2021 in “Regenerative Biomaterials” The hydrogel speeds up skin wound healing and helps regenerate tissue.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
1 citations
,
April 2006 in “International Journal of Oncology” Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
January 2021 in “Annals of translational medicine” YH0618 helped reduce skin and nail problems and fatigue in chemotherapy patients.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
January 2025 in “SSRN Electronic Journal” 14 citations
,
September 1990 in “Journal of the American Academy of Dermatology” Viprostol does not effectively promote hair growth in male pattern baldness.
July 2013 in “Revista da Universidade Vale do Rio Verde” Flutamide treatment showed no significant changes in mice vaginal mucosa.
4 citations
,
March 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” The new drug delivery system improves exemestane's absorption and effectiveness.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
5 citations
,
January 2024 in “BMC Cancer” Anthracycline and taxane chemotherapy cause significant side effects like fatigue, vomiting, nausea, nerve damage, joint pain, and hair loss in breast cancer patients.
December 2023 in “Medical Times” The MEST method increases cell yield and volume for regenerative medicine but needs more testing.
7 citations
,
August 2020 in “Current topics in medicinal chemistry” New cancer treatments aim to reduce side effects and improve effectiveness.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
July 2024 in “Journal of Investigative Dermatology” Combining certain treatments, including FOL005, may improve healing of difficult wounds.
October 2025 in “Dermatology and Therapy” 1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
May 2017 in “Journal of The American Academy of Dermatology” Finasteride and dutasteride increase sexual dysfunction reports.